GlaxoSmithKline requests emergency authorization from FDA for Covid antibody drug

Business

In this article

In this photo illustration the British multinational pharmaceutical company GlaxoSmithKline (GSK) logo seen displayed on a smartphone with a computer model of the COVID-19 coronavirus on the background.
Budrul Chukrut | SOPA Images | Getty Images

GlaxoSmithKline and Vir Biotechnology on Friday applied for an emergency use authorization from the Food and Drug Administration for their monoclonal antibody drug.

The FDA submission is based on an interim analysis of a phase three trial, which evaluated the drug for the early treatment of Covid-19 in adults at high risk of hospitalization. The drug reduced hospitalizations or death from Covid-19 by 85% compared with a placebo.

The two companies in August started testing the antibody on early-stage Covid-19 patients, hoping to keep symptoms from progressing.

This is a developing story. Please check back for updates.

-Reuters contributed to this report.

Articles You May Like

Here’s how the IRS says you should handle 1099-K tax reporting mistakes on your return
Here’s why the U.S. had to sweeten terms to get the SVB sale done
Barbara Corcoran says her struggles in school had a surprising benefit: ‘That’s exactly what built my business and got me rich’
Ford plans to build 500,000 EVs annually at its $5.6 billion Tennessee campus
5 alarming stats on U.S. economic inequality in Pulitzer Prize-winning author’s new book